About 2/3 of melanomas are caused by exposure to UV radiation.  Often the damage is done in the days of our youth, and only manifested later in life.  So if peopl...

To say that a patient failed a treatment is to use fairly common jargon in describing a situation in which the patient is no longer benefitting from that treatment.  T...

WASHINGTON, D.C.— Most melanoma patients never hear about the most cutting edge treatments available to them.  That’s because some of the most innovative a...

The MRF is committed to funding research for finding new treatments that will make a meaningful impact on survival for melanoma patients and understanding ways to improve p...

There’s been much buzz about the new Showtime series, “The Big C” and the portrayal of cancer on the show.  But what do melanoma patients think about...

Amy Harmon, a reporter for The New York Times spoke with the Melanoma Research Foundation’s executive director, Tim Turnham about the promising results and increased ...

The Melanoma Research Foundation (MRF) was pleased to see Laura Linney’s portrayal of a woman with advanced melanoma honored by the Hollywood Foreign Press Associatio...

The New York Times' latest installment in their ongoing coverage of melanoma focuses on the role that patients have in solving the problem of tumor resistance and spotl...

Over the weekend the melanoma community lost a true fighter.  Jenna Bockmiller of California died at the age of 20, after a 6-year battle with melanoma. Her tenacious ...

WASHINGTON— With growing financial and time pressures in medical care, the era of the leisurely doctor’s visit is largely gone.  As visits become increasin...

Roche announced results from a Phase II clinical study of RG7204 (PLX4032), an inhibitor targeting the BRAF protein that is found in half of metastatic melanoma tumors.&nbs...

WASHINGTON, D.C.— For years, treatment options for patients with advanced melanoma have been bleak, with survival averaging around one year after diagnosis.  But...